We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Aktis Oncology Stock

Invest in or calculate the value of your shares in Aktis Oncology or other pre-IPO companies through EquityZen's platform.

Get Started

Aktis Oncology Stock (AKON)

Aktis Oncology is a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals.

About Aktis Oncology Stock

Founded

2021

Headquarters

Boston, MA, US

Industries

Software, Artificial Intelligence, Data and Analytics

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Aktis Oncology Management

Leadership team at Aktis Oncology

Co-founder and Chief Business Officer

Dr. Brian Goodman

Founder

Todd Foley

Locked Features

Join now and verify your accreditation status to gain access to:

  • Aktis Oncology current valuation
  • Aktis Oncology stock price
  • Available deals in Aktis Oncology and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

Trading Aktis Oncology Stock

How to invest in Aktis Oncology stock?

Accredited investors can buy pre-IPO stock in companies like Aktis Oncology through EquityZen funds. These investments are made available by existing Aktis Oncology shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Aktis Oncology stock?

Shareholders can sell their Aktis Oncology stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."